Öztürk Ateş

485 total citations
61 papers, 281 citations indexed

About

Öztürk Ateş is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Öztürk Ateş has authored 61 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 19 papers in Cancer Research. Recurrent topics in Öztürk Ateş's work include Breast Cancer Treatment Studies (16 papers), HER2/EGFR in Cancer Research (14 papers) and Cancer Treatment and Pharmacology (11 papers). Öztürk Ateş is often cited by papers focused on Breast Cancer Treatment Studies (16 papers), HER2/EGFR in Cancer Research (14 papers) and Cancer Treatment and Pharmacology (11 papers). Öztürk Ateş collaborates with scholars based in Türkiye, United States and India. Öztürk Ateş's co-authors include Kadri Altundağ, Taner Babacan, Ali Sever, Furkan Sarici, Neyran Kertmen, Yavuz Özışık, Gökmen Umut Erdem, Süleyman Şahin, Aydın Aytekin and Fatih Karataş and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Öztürk Ateş

45 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Öztürk Ateş Türkiye 9 159 85 76 55 49 61 281
Yukinori Ozaki Japan 11 295 1.9× 102 1.2× 66 0.9× 62 1.1× 38 0.8× 51 385
Constantino Sábado Spain 10 103 0.6× 58 0.7× 67 0.9× 104 1.9× 39 0.8× 28 332
José Carlos Benítez Spain 8 159 1.0× 94 1.1× 46 0.6× 54 1.0× 44 0.9× 39 301
Konstantinos Tsapakidis Greece 9 167 1.1× 59 0.7× 44 0.6× 91 1.7× 34 0.7× 30 289
Márcio Debiasi Brazil 9 115 0.7× 142 1.7× 60 0.8× 37 0.7× 39 0.8× 24 294
Sarah Burkhead Whittle United States 13 110 0.7× 87 1.0× 124 1.6× 228 4.1× 63 1.3× 33 546
Atsuko Kitamura Japan 8 82 0.5× 107 1.3× 42 0.6× 48 0.9× 39 0.8× 19 228
Bruno Kovic Canada 8 56 0.4× 52 0.6× 53 0.7× 73 1.3× 63 1.3× 9 322
Angel Yordanov Bulgaria 9 109 0.7× 70 0.8× 42 0.6× 88 1.6× 92 1.9× 101 411
Emily Hibbitts United States 8 74 0.5× 110 1.3× 70 0.9× 109 2.0× 37 0.8× 17 278

Countries citing papers authored by Öztürk Ateş

Since Specialization
Citations

This map shows the geographic impact of Öztürk Ateş's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Öztürk Ateş with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Öztürk Ateş more than expected).

Fields of papers citing papers by Öztürk Ateş

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Öztürk Ateş. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Öztürk Ateş. The network helps show where Öztürk Ateş may publish in the future.

Co-authorship network of co-authors of Öztürk Ateş

This figure shows the co-authorship network connecting the top 25 collaborators of Öztürk Ateş. A scholar is included among the top collaborators of Öztürk Ateş based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Öztürk Ateş. Öztürk Ateş is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Karaçin, Cengiz, Zuhat Urakçı, Ali Yılmaz, et al.. (2024). Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer. Future Oncology. 20(4). 207–214.
2.
Yıldırım, Hasan Çağrı, Deniz Ateş Özdemir, Deniz Can Güven, et al.. (2024). Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab. SHILAP Revista de lepidopterología. 24(4). 998–1003. 1 indexed citations
3.
4.
Ateş, Öztürk, et al.. (2023). Efficacy and Safety of Combined Chemotherapy Regimens with Bevacizumab in Platinum-sensitive Ovarian Cancers. Journal of College of Physicians And Surgeons Pakistan. 33(9). 1006–1011.
5.
Ateş, Öztürk, et al.. (2023). Novel inflammatory markers and prognostic importance of platinum-sensitive ovarian carcinoma relapse. SHILAP Revista de lepidopterología. 151(7-8). 419–422. 1 indexed citations
6.
Doğan, Mutlu, et al.. (2023). 288P Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience. Annals of Oncology. 34. S299–S300. 1 indexed citations
7.
Ateş, Öztürk, et al.. (2022). Platelet-to-Lymphocyte Ratio as an Indicator to Predict Decreased Carbon Monoxide Diffusion of the Lung in Patients with Testicular Cancer. Journal of College of Physicians And Surgeons Pakistan. 32(3). 369–372. 1 indexed citations
8.
Ateş, Öztürk, et al.. (2022). Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib. Journal of Oncology Pharmacy Practice. 28(8). 1906–1909.
9.
Ateş, Öztürk, et al.. (2022). Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data.. PubMed. 26(4). 1398–1404. 2 indexed citations
10.
Yekedüz, Emre, et al.. (2022). Vortex keratopathy associated with ribociclib. Journal of Oncology Pharmacy Practice. 29(1). 230–232. 5 indexed citations
11.
Ateş, Öztürk, et al.. (2021). Clinical Outcomes and Prognostic Factors in HER-2 Positive Breast Cancer with Brain Metastasis: A Single-centre Experience. Journal of College of Physicians And Surgeons Pakistan. 31(2). 166–170. 5 indexed citations
12.
Ateş, Öztürk, et al.. (2021). CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer. Journal of College of Physicians And Surgeons Pakistan. 31(3). 326–329. 8 indexed citations
13.
Dızdar, Ömer, Nuriye Özdemir, Nurullah Zengin, et al.. (2019). The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy. Anti-Cancer Drugs. 30(3). 289–294. 2 indexed citations
14.
Sarici, Furkan, Taner Babacan, Hakan Büyükhatipoğlu, et al.. (2017). Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience.. PubMed. 21(4). 826–831.
15.
Gündüz, Mehmet, Öztürk Ateş, Taner Babacan, et al.. (2017). Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients.. PubMed. 21(4). 799–808.
16.
Ateş, Öztürk, Taner Babacan, Neyran Kertmen, et al.. (2016). Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.. PubMed. 21(2). 375–81. 7 indexed citations
17.
Büyükhatipoğlu, Hakan, Taner Babacan, Neyran Kertmen, et al.. (2015). A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.. PubMed. 20(1). 22–7. 5 indexed citations
18.
Kertmen, Neyran, Taner Babacan, Özge Keskin, et al.. (2015). Molecular subtypes in patients with inflammatory breast cancer; a single center experience.. PubMed. 20(1). 35–9. 16 indexed citations
19.
Babacan, Taner, Hakan Büyükhatipoğlu, Neyran Kertmen, et al.. (2015). Chemotherapy might not be beneficial in lymph node- negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis.. PubMed. 20(2). 479–86. 2 indexed citations
20.
Babacan, Taner, Orhan Efe, Hakan Büyükhatipoğlu, et al.. (2015). Efficacy of Capecitabine Monotherapy as the First-line Treatment of Metastatic HER2-negative Breast Cancer. Tumori Journal. 101(4). 418–423. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yukinori Ozaki Breakdown of academic impact, for papers by Constantino Sábado Breakdown of academic impact, for papers by José Carlos Benítez Breakdown of academic impact, for papers by Konstantinos Tsapakidis Breakdown of academic impact, for papers by Márcio Debiasi Breakdown of academic impact, for papers by Sarah Burkhead Whittle Breakdown of academic impact, for papers by Atsuko Kitamura Breakdown of academic impact, for papers by Bruno Kovic Breakdown of academic impact, for papers by Angel Yordanov Breakdown of academic impact, for papers by Emily Hibbitts
Rankless by CCL
2026